Daniela Salvemini, Ph.D., Professor of Pharmacology & Physiology and her research team published a paper in the Journal of Experimental Medicine detailing their studies on chemotherapy induced neuropathic pain (CINP) caused by a treatment used for multiple myeloma.

A chemotherapy drug, bortezomib, used to treat multiple myeloma and mantle cell lymphoma causes CINP in over 40% of patients. Using an animal model, investigators found that bortezomib increases sphingolipid production and that two metabolites of this molecule accumulate in the spinal cord. These metabolites, sphingosine 1-phosphate and dihydrosphigosine 1-phosphate, activate S1PR1 on the surface of astrocytes and cause neuorinflammation.

An oral drug used to treat multiple sclerosis (MS), finglolimod, inhibits S1PR1 without affecting the chemotherapeutic actions of bortezomib, and may even inhibit tumor growth.

For more information, read the full article in Newslink.